Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance

LIFECORE BIOMEDICAL, INC. DE

2026-Q1 EPS reported -$0.43 revenue$23,193,000

Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.
Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.
Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.
Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LIFECORE BIOMEDICAL, INC. DE reported first quarter ended March 31, 2026 results: revenue $23.2 million, net income $15.0 million, EPS $0.43 of loss per diluted share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $23.2 million
Net income: $15.0 million
EPS: $0.43 of loss per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the year,” stated Paul Josephs, President and Chief Executive Officer of Lifecore. Financial Snapshot and Recent Developments • Revenues for the first quarter of 2026 were $23.2 million , a decrease of $12.0 million, or 34%, compared to $35.2 million for the comparable prior year quarter ended February 23, 2025. • Gross profit margin for the first quarter of

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.